Enhancing T cell reconstitution after hematopoietic stem cell transplantation: A brief update of the latest trends Review uri icon


MeSH Major

  • Hematopoietic Stem Cell Transplantation
  • Regeneration
  • T-Lymphocytes


  • Hematopoietic stem cell transplantation (HSCT) is associated with a period of immune incompetence that particularly affects the T cell lineage. Strategies to enhance T cell reconstitution could significantly improve the survival of HSCT recipients by decreasing the incidence of fatal infectious complications and by enhancing graft-versus-tumor activity. In recent years, a variety of promising strategies have been established in preclinical models to improve T cell recovery in particular after allogeneic T cell-depleted HSCT, without aggravating graft-versus-host disease while preserving or even improving graft-versus-tumor activity. These therapies include treatment with keratinocyte growth factor (KGF), growth hormone (GH), LHRH agonists, interleukin 7 (IL-7) and interleukin 15 (IL-15). Thanks to the establishment of Notch-based culture systems, adoptive cellular therapies with T lineage-committed precursor cells have become feasible, since early T cell progenitors can now easily be generated in vitro in large quantities and have been proven to be very effective in enhancing T cell reconstitution and anti-tumor activity after allogeneic T cell-depleted HSCT. The translation of most of these strategies into clinical trials is likely and in some cases Phase I/II studies are already underway.

publication date

  • January 2008



  • Review



  • eng

PubMed Central ID

  • PMC2684110

Digital Object Identifier (DOI)

  • 10.1016/j.bcmd.2007.07.015

PubMed ID

  • 17905611

Additional Document Info

start page

  • 44

end page

  • 7


  • 40


  • 1